Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7265489 | 0.98 | PARP1 (0.72) | PARP1RORCHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL30251654 | 0.89 | PARP1 (0.60) | PARP1RORCHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL984448 | 0.89 | PARP1 (0.60) | PARP1RORCHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL7322972 | 0.88 | PARP1 (0.58) | PARP1RORCALDH1A1ALOX15FABP4 | |
| SCHEMBL7471201 | 0.86 | PARP1 (0.57) | PARP1RORCALDH1A1FABP4 | |
| SCHEMBL21804730 | 0.86 | PARP1 (0.70) | PARP1RORCHCRTR1HCRTR2MGLL | |
| Edetic Acid SCHEMBL8352008 | 0.85 | PARP1 (0.56) | PARP1RORCHCRTR1HCRTR2ALOX15 | |
| SCHEMBL1502069 | 0.85 | PARP1 (1.00) | PARP1RORCHCRTR1HCRTR2ALDH1A1 | |
| Oxalic Acid SCHEMBL17978250 | 0.84 | PARP1 (0.90) | PARP1RORCHCRTR1HCRTR2MGLL | |
| SCHEMBL3360298 | 0.84 | PARP1 (0.72) | PARP1RORCHCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 579 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387365-A1 | Combination Treatment Of Arthritic Disease | SYNACT PHARMA APS (DK) | 2025-12-25 | — | — | US | claimed |
| US-20250302804-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SYNACT PHARMA APS (DK) | 2025-10-02 | — | — | US | claimed |
| EP-4119140-B1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES IN COMBINATION WITH METHOTREXATE FOR USE IN THE TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2025-06-25 | — | — | EP | claimed |
| WO-2025124760-A1 | TREATMENT OF SUBPOPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-06-19 | — | — | WO | claimed |
| EP-4522160-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SynAct Pharma ApS (DK) | 2025-03-19 | — | — | EP | claimed |
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-01-30 | — | — | US | claimed |
| EP-4440572-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SynAct Pharma ApS (DK) | 2024-10-09 | — | — | EP | claimed |
| WO-2023218048-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SYNACT PHARMA APS (DK) | 2023-11-16 | — | — | WO | claimed |
| WO-2023094692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2023-06-01 | — | — | WO | claimed |
| US-20230149351-A1 | TREATMENT OF SYMPTOMATIC VIRAL DISEASES | SYNACT PHARMA APS (DK) | 2023-05-18 | — | — | US | claimed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| EP-0554436-B1 | GABA RECEPTOR MODULATORS | EURO CELTIQUE SA (LU) | 2000-07-05 | — | — | EP | claimed |
| EP-0784619-A1 | PHENYL-OXO-ALKYL-(4-PIPERIDINYL)BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010026-A1 | PHENYL-OXO-ALKYL-(4-PIPERIDINYL)BENZOATE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-04-04 | — | — | WO | claimed |
| US-5156686-A | Treating with carboxylic acid, conversion to water soluble salt, removing entrained oil in aqueous phase | UNION OIL COMPANY OF CALIFORNIA (US) | 1992-10-20 | — | — | US | claimed |
| EP-0234872-B1 | CARBOXAMIDES USEFUL AS ANTIEMETIC OR ANTIPSYCHOTIC AGENTS | Erbamont Inc. (US) | 1991-11-27 | — | — | EP | claimed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | MTX1, MTX2, SYVN1 | PARP1 1877/4885RORC 71/4885HCRTR1 3284/4885 |
| US-20250302804-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | AGT, REN, EDNRB | PARP1 1127/4885RORC 1371/4885HCRTR1 4178/4885 |
| US-20230149351-A1 | TREATMENT OF SYMPTOMATIC VIRAL DISEASES | ACE2, ACE, SARS1 | PARP1 2433/4885RORC 1912/4885HCRTR1 1966/4885 |
| US-20250387365-A1 | Combination Treatment Of Arthritic Disease | ME1, SUCNR1, CPS1 | PARP1 3520/4885RORC 362/4885HCRTR1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.